Actively Recruiting
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
Led by Tanta University · Updated on 2025-05-07
80
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this prospective cohort study is to evaluate the role of transient elastography (Fibroscan) in predicting the response of immunotherapy in advanced Hepatocellular carcinoma (HCC) patients. Researchers will predict the response to 6 months of HCC immunotherapy regarding improvement of the degree of liver fibrosis, development of liver decompensation, complications, survival, and mortality. Participants will undergo history-taking, clinical examination, laboratory investigations, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, Triphasic CT abdomen with contrast or MRI (for evaluation of tumor site, size and number), and Fibroscan examination at baseline and follow-up after 6 months.
CONDITIONS
Official Title
Fibroscan Evaluating Immunotherapy Response in Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with confirmed advanced HCC diagnosed by two imaging methods or liver biopsy who are eligible for immunotherapy
- Preserved liver function with compensated Child-Pugh A if cirrhosis is present
- Performance status of 2 or less at staging
- No high-risk signs for bleeding on upper endoscopy, such as treated oesophageal varices and no history of variceal bleeding
You will not qualify if you...
- Previous locoregional therapy or liver transplantation
- Child-Pugh class C liver function
- Performance status greater than 2 at staging
- Presence of vascular disorders, arterial hypertension, or risk of variceal bleeding
- Severe autoimmune disorders
- Lost to follow-up
- Pregnant or breastfeeding women
- Unwillingness to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tanta University Hospitals
Tanta, Gharbyea, Egypt, 31516
Actively Recruiting
Research Team
R
Rania M Elkafoury, MD
CONTACT
N
Nabila A Elgazzar, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here